Physician profile
Kiersti Devaney
NPI 1073280277
$719.64
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $548 · 2023: $141 · 2024: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135.49 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $89.55 | 2022 | |
| Bausch Health US, LLC | $64.67 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $52.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $50.72 | 2023 | Spravato, Xarelto |
| Novo Nordisk INC | $41.81 | 2022 | |
| Gilead Sciences, INC. | $31.89 | 2022 | |
| Nevro Corp. | $30.65 | 2024 | Senza |
| Sanofi Pasteur INC. | $28.50 | 2023 | |
| Amgen INC. | $23.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.51 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.40 | 2023 | |
| Glaxosmithkline, LLC. | $20.21 | 2023 | Arexvy, Shingrix, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $18.93 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $18.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.71 | 2022 | |
| Antares Pharma, INC. | $15.70 | 2022 | |
| Currax Pharmaceuticals LLC | $13.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiersti Devaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.